Search - tctmd.com

Displaying 601 - 620 of 868

Sort: Relevancy | Date

Presentation TCT 2014

Case #6: BRS: One Scaffold vs Two Scaffolds/Stents

Presenter: Shao Liang Chen, Issam D. Moussa, Leif Thuesen, Jean Fajadet

September 16, 2014

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Presenter: Armando P?rez de Prado

September 16, 2014

Presentation TCT 2014

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Presenter: Alok Saurav

September 16, 2014

Presentation TCT 2014

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Presenter: Christian Heeger

September 16, 2014

Presentation TCT 2014

Comparison of sirolimus-eluting stents with biodegradable polymer versus zotarolimus-eluting stents with durable polymer assessed by optical coherence tomography: The ALSTER-OCT___

Presenter: Christian Heeger

September 16, 2014

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2014

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Presenter: Clemens von Birgelen

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Presenter: Ming Kai Lam

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Presentation TCT 2014

Endothelialization of the Multilayer Flow Modulator Versus Single-Layer Arterial Stents

Presenter: Edel Kavanagh

September 16, 2014

Presentation TCT 2014

Cost Comparisons of Invasive and Non-Invasive Diagnostic Evaluations for Patients with Suspected In-Stent Restenosis Following Implant of Metallic Stents and Bioresorbable___

Presenter: James Min

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

Presentation TCT 2014

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

Presenter: Kazuyuki Yahagi

September 16, 2014

News Conference News TCT 2014

EXCITE ISR: Laser Atherectomy Superior to Angioplasty Alone for Femoropopliteal In-Stent Restenosis

September 16, 2014

Presentation TCT 2014

Choice of Metallic DES Stents for Bifurcation Stenting

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Francesco Burzotta

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Conference News TCT 2014

Marie-Claude Morice, MD, Receives 2014 Master Clinical Operator Award

September 15, 2014

Advertisement

Case #6: BRS: One Scaffold vs Two Scaffolds/Stents

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Comparison of sirolimus-eluting stents with biodegradable polymer versus zotarolimus-eluting stents with durable polymer assessed by optical coherence tomography: The ALSTER-OCT___

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Endothelialization of the Multilayer Flow Modulator Versus Single-Layer Arterial Stents

Cost Comparisons of Invasive and Non-Invasive Diagnostic Evaluations for Patients with Suspected In-Stent Restenosis Following Implant of Metallic Stents and Bioresorbable___

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

EXCITE ISR: Laser Atherectomy Superior to Angioplasty Alone for Femoropopliteal In-Stent Restenosis

Choice of Metallic DES Stents for Bifurcation Stenting

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

Marie-Claude Morice, MD, Receives 2014 Master Clinical Operator Award

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content